Results 211 to 220 of about 631,529 (311)

Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling. [PDF]

Int J Mol Cell Med
Haki M, Bayat R.
europepmc   +1 more source

A Unique Case of Intracranial Amelanotic Melanoma with BRAF V600E Mutation Successfully Treated via Molecular-targeted Therapy. [PDF]

NMC Case Rep J, 2023
Fujita J, Tomita Y, Ichimura K, Yamasaki R, Nishigaki S, Nitta Y, Inoue Y, Sotome Y, Kidani N, Muraoka K, Hirotsune N, Nishino S.   +11 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study. [PDF]

Immunotargets Ther
Liu J, Wang Y, Cui L, Nie Y, Li C, Tan W, Li Y, Bai Y, Wan T, Hu B, Liu Z, Hu M, Wang M, Duan F.   +13 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

[Molecular targeted therapy for progressive low-grade gliomas in children]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Sun YL, Li M, Liu JJ, Gao WC, Wu YF, Wan LL, Ren SQ, DU SX, Wu WS, Sun LM.   +9 more
europepmc   +1 more source

Editorial: Molecular Targeted Therapy in Oncology: Lessons From Pharmacogenetics and Pharmacoepigenetics. [PDF]

Front Mol Biosci, 2022
Imani S, Becatti M, Khan MA.
europepmc   +1 more source

Molecular target therapy for malignant tumor 1) The molecular target therapy.

Nihon Naika Gakkai Zasshi, 2005
openaire   +2 more sources

Pathology confronts molecular targeted therapies [PDF]

Nature Clinical Practice Oncology, 2006
openaire   +2 more sources

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source